Early Return to Profitability and Breakthrough Growth
First written in FY2017. 12 of 27 entries say "Restated". Latest entry: 2026-08-13.
No other company in this theme has enough history to compare yet.
- FY2025Profit recovery target maintained despite wider lossesAnnual report
「Going forward, the company aims to restore profitability by strengthening its manufacturing structure to handle the culture and processing of a wide variety of cells and expanding the business.」
The loss in the cell processing business segment widened from ¥373 million in the previous fiscal year to ¥474 million, but the company continues to target a return to profitability through a stronger manufacturing structure and business expansion. - FY2025-H1RestatedAnnual report
「The company aims to restore segment profitability by recovering revenue through increased contract work for specified cell processing products and the acquisition of new CDMO projects, as well as by reducing costs through optimization of the manufacturing structure and improving the efficiency of selling expenses.」
The company continues to target a return to profitability in the cell processing business segment and explicitly identified increased contract work for specified cell processing products, new CDMO projects, cost reductions and greater efficiency in selling expenses as means of achieving this. - FY2024-Q2Profit recovery target maintained despite wider lossesAnnual report
「In the cell processing business segment, the company is optimizing its manufacturing structure through the consolidation and closure of cell processing facilities and other measures, and aims to restore segment profitability at an early stage.」
The company continues to target an early return to profitability in the cell processing business segment and to optimize its manufacturing structure through facility consolidation and other measures, but the segment loss for the six months ended the second quarter widened from ¥133 million in the same period of the previous year to ¥154 million. - FY2024-Q1AdvancedAnnual report
「Through the business structural reforms implemented in April 2018, the company is optimizing its manufacturing structure in the cell processing business segment through the consolidation and closure of cell processing facilities and other measures, with the aim of restoring segment profitability at an early stage.」
The company continues to target an early return to profitability in the cell processing business segment and to optimize its manufacturing structure through facility consolidation and other measures. In the first quarter, the segment loss narrowed from ¥57 million in the same period of the previous year to ¥31 million, but the segment did not become profitable. - FY2023RestatedAnnual report
「Going forward, the company aims to achieve an early return to profitability by strengthening its manufacturing structure to handle the culture and processing of a wide variety of cells and expanding the business.」
The cell processing business segment recorded a loss of ¥346 million, but the company continues to target an early return to profitability through a stronger manufacturing structure capable of handling a wide variety of cells. - FY2023-Q3RestatedAnnual report
「In the cell processing business segment, the company is optimizing its manufacturing structure through the consolidation and closure of cell processing facilities and other measures, and aims to restore segment profitability at an early stage.」
The company continues to target an early return to profitability in the cell processing business segment by optimizing its manufacturing structure through the consolidation and closure of cell processing facilities and other measures. - FY2023-Q2RestatedAnnual report
「In the cell processing business segment, the company is optimizing its manufacturing structure through the consolidation and closure of cell processing facilities and other measures, and aims to restore segment profitability at an early stage.」
The company continues to target an early return to profitability in the cell processing business segment by optimizing its manufacturing structure through facility consolidation and other measures. - FY2023-Q1RestatedAnnual report
「However, the company is steadily implementing the business structural reforms launched in April 2018 and, in the cell processing business segment, is optimizing its manufacturing structure through the consolidation and closure of cell processing facilities and other measures, with the aim of restoring segment profitability at an early stage.」
The company continues to target a return to profitability in the cell processing business segment and to pursue its policy of optimizing the manufacturing structure through facility consolidation and other measures. - FY2022Losses widen despite continued target of returning to profitabilityAnnual report
「During the fiscal year, the company continued to aim for segment profitability, as it had in the previous fiscal year. However, in addition to a decline in revenue due to the impact of COVID-19, increased costs for developing the infrastructure for cell culture and processing resulted in a segment loss of ¥232 million for the fiscal year, compared with a segment loss of ¥132 million in the previous fiscal year. Going forward, the company aims to achieve an early return to profitability by strengthening its manufacturing structure to handle the culture and processing of a wide variety of cells and expanding the business.」
The company continues to target a return to profitability in the cell processing business segment, but the full-year loss worsened from ¥132 million to ¥232 million. It identified strengthening the manufacturing structure to handle a wide variety of cells as a means of achieving this. - FY2022-Q3RestatedAnnual report
「The company is steadily implementing the business structural reforms launched in April 2018 and, in the cell processing business segment, is optimizing its manufacturing structure through the consolidation and closure of cell processing facilities and other measures, with the aim of restoring segment profitability at an early stage.」
While losses in the cell processing business segment are widening, the company continues to target an early return to profitability through facility consolidation and other measures. - FY2022-Q2RestatedAnnual report
「The company is steadily implementing the business structural reforms launched in April 2018 and, in the cell processing business segment, is optimizing its manufacturing structure through the consolidation and closure of cell processing facilities and other measures, with the aim of restoring segment profitability at an early stage.」
The company continues to target an early return to profitability in the cell processing business segment by optimizing its manufacturing structure through the consolidation and closure of cell processing facilities and other measures. - FY2022-Q1RestatedAnnual report
「In the cell processing business segment, the company is optimizing its manufacturing structure through the consolidation and closure of cell processing facilities and voluntary retirement programs, among other measures, and aims to restore segment profitability at an early stage.」
The company continues to target an early return to profitability in the cell processing business segment through structural reforms, including facility consolidation and voluntary retirement programs. - FY2021-Q3RestatedAnnual report
「The company aims to restore segment profitability in the cell processing business segment.」
While the cell processing business segment recorded a loss of ¥88 million for the nine months ended the third quarter, the company continues to target a return to profitability. - FY2021-Q2RestatedAnnual report
「However, by steadily implementing its business structural reforms, the company has been optimizing its manufacturing structure in the cell processing business segment through the consolidation and closure of cell processing facilities and voluntary retirement programs, among other measures, and aims to restore segment profitability.」
While the cell processing business segment recorded a loss of ¥90 million for the six months ended the second quarter, the company continues to target a return to profitability through facility consolidation and other measures. - FY2021-Q1From profitability to a target of returning to profitabilityAnnual report
「The company aims to restore segment profitability in the cell processing business segment.」
The cell processing business segment, which had been profitable through the previous fiscal year, posted a loss of ¥55 million in the first quarter, and the wording changed to a target of returning to profitability. - FY2020-Q3AdvancedAnnual report
「Through greater efficiency in selling, general and administrative expenses and other measures resulting from the thorough implementation and strengthening of business structural reforms, segment profit was ¥28 million, up 73.9% year on year.」
The cell processing business segment increased profit from ¥16 million in the same period of the previous year to ¥28 million due to the effects of business structural reforms, remaining profitable. - FY2020-Q2AdvancedAnnual report
「As a result of the effects of business structural reforms implemented in the previous fiscal year and other factors, segment profit was ¥79 million, compared with a segment loss of ¥0 million in the same period of the previous year.」
The cell processing business segment, which was targeted for an early return to profitability, recorded a profit of ¥79 million for the six months ended the second quarter. - FY2020-Q1RestatedAnnual report
「By steadily implementing the business structural reforms launched in April 2018, the company optimized its manufacturing structure in the cell processing business segment through the consolidation and closure of cell processing facilities and voluntary retirement programs, among other measures, and achieved segment profitability in the segment during the three months ended the first quarter, continuing from the previous fiscal year.」
The company stated that the cell processing business segment achieved profitability in the first quarter as it had in the previous fiscal year. - FY2019AchievedAnnual report
「The company achieved segment profitability in the cell processing business segment during the fiscal year.」
The cell processing business segment achieved segment profitability through structural reforms, including facility consolidation and voluntary retirement programs. - FY2019-Q3AdvancedAnnual report
「As a result of substantial improvements in earnings from the consolidation of cell culture and processing facilities and optimization of personnel allocation through structural reforms, revenue was ¥752 million and segment profit was ¥16 million.」
Through the consolidation of cell culture and processing facilities and optimization of staffing, the cell processing business segment posted a profit of ¥16 million for the nine months ended the third quarter, demonstrating concrete progress toward the profitability target. - FY2019-Q2AdvancedAnnual report
「The Shin-Yokohama and Osaka cell culture and processing facilities were consolidated by March 2019 into the Shinagawa Cell Culture and Processing Facility, which has one of the largest manufacturing capacities in Japan. Going forward, by handling everything from cell processing for medical institutions to the manufacture of regenerative medicine products, the company aims to improve the efficiency of its manufacturing structure in the cell processing business and achieve break-even in the cell processing business segment for the fiscal year ending September 2019.」
The company completed facility consolidation by March 2019 toward an early return to profitability and break-even, and continues to target break-even for the fiscal year ending September 2019. - FY2019-Q1AdvancedAnnual report
「In addition, as earnings improved significantly through structural reforms, including the consolidation of cell culture and processing facilities and optimization of staffing, revenue was ¥246 million and the segment loss was ¥9 million.」
Through facility consolidation and optimization of staffing, the cell processing business segment reduced its loss to ¥9 million. The company did not state that break-even had been achieved. - FY2018-Q3RestatedAnnual report
「The Shin-Yokohama and Osaka cell culture and processing facilities were consolidated by March 2019 into the Shinagawa Cell Culture and Processing Facility, which has one of the largest manufacturing capacities in Japan. By handling everything from cell processing to the manufacture of regenerative medicine products, the company aims to improve the efficiency of its manufacturing structure and achieve an early break-even point.」
The company continues to target manufacturing efficiency through facility consolidation and an early return to break-even. - FY2018-Q2AdvancedAnnual report
「The Shin-Yokohama and Osaka cell culture and processing facilities will be consolidated by March 2019 into the Shinagawa Cell Culture and Processing Facility (the “Shinagawa CPF”), which has one of the largest manufacturing capacities in Japan. By handling everything from cell processing for medical institutions to the manufacture of regenerative medicine products, the company aims to improve the efficiency of its manufacturing structure in the cell processing business and achieve break-even in the cell processing business segment for the fiscal year ending September 2019.」
The previous early-return-to-profitability target was made more specific as a time-bound target of achieving break-even in the cell processing business segment for the fiscal year ending September 2019, based on facility consolidation. - FY2017First statedAnnual report
「By expanding into new business areas, including cell processing for companies and other customers, we will aim to achieve profitability at an early stage. In addition, by accelerating the development of cell therapy products and obtaining marketing approval, we will aim for significant growth.」
The Company established medium- to long-term goals of achieving early profitability through expansion of the cell-processing business and significant growth through approval of cell therapy products.